Other News

CardioFocus Announces The Publication Of HeartLight X3 Pivotal Study Data

HeartLight® X3 System Has Significantly Shorter Procedure Times for Atrial Fibrillation Ablation MARLBOROUGH, Mass., Feb. 25, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that results from its HeartLight® X3 Pivotal Study were published in the premier journal Circulation: Arrhythmia and Electrophysiology (CircEP), which features […]

BGF announces multi-million investment in Vasorum – high-growth medical device business based in Dublin Ireland

BGF announces multi-million investment in Vasorum – high-growth medical device business based in Dublin Ireland DUBLIN, IRELAND, February 25, 2021 /EINPresswire.com/ — BGF announces multi-million investment in Vasorum – high-growth Medical device business based in Dublin 7th Irish investment by BGF in 2 years Thursday 25th February 2021 BGF – […]

New Study Finds Zio by iRhythm 10x More Effective in Proactively Identifying Atrial Fibrillation and Increasing Detection

Wearable cardiac monitoring solution enables early detection and treatment of arrhythmia based on risk factors, according to results of the SCREEN-AF study published in JAMA Cardiology LONDON–(BUSINESS WIRE)–iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the results of a brand […]

Occlutech announces Completion of Patient Enrolment in Pilot Study of Atrial Flow Regulator (AFR) in Patients with Heart Failure

SCHAFFHAUSEN, Switzerland, Feb. 24, 2021 /PRNewswire/ — Occlutech, a privately-held company, announced today the completion of patient enrolment in its pilot study to assess safety and efficacy of the novel Atrial Flow Regulator (AFR) in heart failure (HF) patients (PRELIEVE trial). PRELIEVE is a prospective, multicenter, open-label, non-randomized pilot study that evaluates the […]

Terumo Signs a Definitive Agreement to Acquire All Assets of Health Outcomes Sciences, Inc.

– Transaction furthers Terumo’s efforts to improve patient outcomes and decrease healthcare costs through personalized predictive analytics and clinical decision support at the point of care – TOKYO, Feb. 23, 2021 /PRNewswire/ — Terumo Corporation (TSE: 4543), a global leader in medical technology, has signed a definitive agreement to acquire all […]

United Therapeutics Corporation Reports Fourth Quarter And Full Year 2020 Financial Results

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2020. Full year net revenue rose to $1,483 million, as U.S. patients being treated with the company’s treprostinil-based therapies reached an all-time high during the […]

Longeveron Announces Successful Completion of Phase 1 Clinical Study of Lomecel-B Intramyocardial Injection in Hypoplastic Left Heart Syndrome Patients

Intramyocardial injection of Lomecel-B well-tolerated, with no major cardiac events, and no serious adverse events related to Lomecel-B reported Full results of the Phase 1 clinical trial expected to be released in Q2 2021 Phase 2 trial expected to commence in Q3 2021 MIAMI, Feb. 24, 2021 (GLOBE NEWSWIRE) — […]

InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States

TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct […]

ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update

Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third Quarter Over 21,000 Patients on NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Tablets in the U.S. CLEAR Outcomes Study Design Highlighted in The American Heart Journal and Progresses Uninterrupted Despite Pandemic […]